Opthea Limited (OPT)
NASDAQ: OPT · IEX Real-Time Price · USD
2.120
+0.050 (2.42%)
At close: Jul 19, 2024, 4:00 PM
2.170
+0.050 (2.36%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Opthea Revenue
In the fiscal year ending June 30, 2023, Opthea had annual revenue of $385.28K with 93.60% growth.
Revenue (ttm)
$385.28K
Revenue Growth
+93.60%
P/S Ratio
792.21
Revenue / Employee
$16,053
Employees
24
Market Cap
305.22M USD
Revenue Chart
* The company reports in AUD currency but revenue data is shown in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2023 | 385.28K | 186.27K | 93.60% |
| Jun 30, 2022 | 199.01K | 103.44K | 108.24% |
| Jun 30, 2021 | 95.56K | -5.13K | -5.09% |
| Jun 30, 2020 | 100.69K | -610.08K | -85.83% |
| Jun 30, 2019 | 710.77K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| OraSure Technologies | 304.64M |
| Sutro Biopharma | 154.07M |
| Pulmonx | 72.99M |
| Enanta Pharmaceuticals | 72.88M |
| SOPHiA GENETICS | 64.18M |
| MacroGenics | 43.36M |
| Adaptimmune Therapeutics | 18.36M |
| Verrica Pharmaceuticals | 8.91M |
OPT News
- 5 days ago - Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board - GlobeNewsWire
- 7 days ago - Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer - GlobeNewsWire
- 4 weeks ago - Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens - GlobeNewsWire
- 5 weeks ago - Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹) - GlobeNewsWire
- 5 weeks ago - Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹) - GlobeNewsWire
- 7 weeks ago - Opthea To Present at Clinical Trials at the Summit Meeting - GlobeNewsWire
- 7 weeks ago - Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD - GlobeNewsWire
- 2 months ago - Opthea Announces Upcoming Presentations at the Retina World Congress 2024 - GlobeNewsWire